ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. Lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Lupuzor ™ has 'Gold Standard' approval from the US FDA for its Phase III trial with a Special Protocol Assessment and "Fast Track" designation. Lupuzor ™ has now commenced its Phase III pivotal trial.

Type
Public
HQ
London, GB
Size (employees)
10 (est)
Immupharma is headquartered in London, GB
Report incorrect company information

Immupharma Office Locations

Immupharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
50 Broadway
Mulhouse, FR
5 Rue du Rhône
Sarnen, CH
10 Poststrasse
Show all (3)
Report incorrect company information

Immupharma Financials and Metrics

Immupharma Revenue

Immupharma's revenue was reported to be £150.46 k in FY, 2017
GBP

Revenue (FY, 2017)

150.5 k

Net income (FY, 2017)

(6.2 m)

EBITDA (FY, 2017)

(7.1 m)

EBIT (FY, 2017)

(7.2 m)

Cash (31-Dec-2017)

2.7 m
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.4 k63.2 k57.1 k22.1 m32.5 k16.8 k184.8 k76.4 k164.8 k150.5 k

Revenue growth, %

(59%)

Operating expense total

(1.5 m)3.6 m4.6 m11.8 m4.2 m(3.8 m)3.6 m4.6 m6.8 m7.4 m

EBITDA

(2 m)(3.5 m)(4.5 m)10.3 m(4.1 m)3.9 m(4.1 m)(4.2 m)(3.3 m)(4.4 m)(6.5 m)(7.1 m)
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1 1 1 978.2 k1 m2.7 m2.9 m12.5 m22.5 m15.6 m12.2 m8.9 m5.4 m5.4 m833.4 k1.9 m2.7 m

Accounts Receivable

3.2 k22.2 k2.8 k13.2 k

Current Assets

1 1 1 979.9 k1 m2.9 m3.3 m12.6 m23.9 m16.8 m13.5 m9.8 m6.5 m6.1 m2.4 m6 m4.4 m

PP&E

12 k12.8 k13.3 k9.3 k76.8 k125.4 k114.8 k97.1 k366.4 k280.1 k231.9 k161.4 k
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

1.4 k15.1 k(2.5 m)(3.1 m)4.7 m8.1 m(2 m)(3.4 m)(3.8 m)(3.7 m)(2.9 m)(3.9 m)(5.3 m)(6.2 m)

Cash From Operating Activities

15.8 k18.3 k879.6 k3.8 m(3.6 m)12 m(6.8 m)(3.4 m)(3.3 m)(3.9 m)(2.5 m)(4.1 m)(6.5 m)(4.4 m)

Cash From Financing Activities

977 k3 m(77.6 k)12 m(143.5 k)555.2 k165.3 k356.9 k191.5 k3 m(310.1 k)7.4 m5.4 m

Net Change in Cash

978.2 k27.1 k2.7 m3.7 m8.5 m11.9 m(6.4 m)(3.2 m)(2.8 m)(3.7 m)199 k(4.5 m)896.3 k945.9 k
GBPY, 2017

Revenue/Employee

15 k

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Immupharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Immupharma Company Life and Culture

Report incorrect company information